In 2007, Raftery, et al. reported in the British Journal of Ophthalmology that, unless ranibizumab is 2.5 times more effective the bevacizumab, ranibizumab is not cost-effective.
En 2007, publicouse que, a menos que o ranibizumab sexa 2,5 veces máis efectivo que o bevacizumab, o ranibizumab non terá un beneficio custo/efectividade.